EPISODE · Mar 12, 2026 · 1 MIN
ACT Brief: Trial Transparency and Synthetic Controls, Readiness as Leading Risk Indicator, FDA Streamlines Biosimilar Pathway
from Applied Clinical Trials · host Applied Clinical Trials
In today's ACT Brief, we explore the transparency demands of complex trial designs and synthetic controls, how measuring site readiness during training predicts protocol execution, and the FDA's streamlined biosimilar development pathway aimed at reducing drug costs.
Embed this episode
Ready to play
ACT Brief: Trial Transparency and Synthetic Controls, Readiness as Leading Risk Indicator, FDA Streamlines Biosimilar Pathway
0:00
1:53
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Applied Clinical Trials?
This episode is 1 minute long.
When was this Applied Clinical Trials episode published?
This episode was published on March 12, 2026.
Can I download this Applied Clinical Trials episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!